FDA cracks down on telehealth weight-loss drug marketing

Regulators say some firms falsely implied their products were equivalent to FDA-approved medications such as Wegovy, Ozempic, Zepbound, and Mounjaro.

The U.S. Food and Drug Administration has intensified its campaign against the booming online weight-loss drug industry, issuing warning letters to 25 telehealth companies that allegedly made false or misleading claims about compounded versions of popular GLP-1 medications.

The letters, posted by the agency this week, targeted telehealth firms that market compounded versions of semaglutide and tirzepatide—the active ingredients in blockbuster drugs including Wegovy, Ozempic, Zepbound, and Mounjaro. Companies receiving warnings included Medica Weight Loss, Ready Med, Clover Meds and others, Reuters reported.

According to the FDA, some companies claimed their compounded products were sourced from FDA-approved pharmacies, had been clinically studied, or were essentially the same as FDA-approved GLP-1 drugs. Regulators said such representations are inaccurate and could mislead consumers seeking weight-loss treatments.

“Patients deserve to know what they're getting,” Michael Davis, acting director of the FDA's Center for Drug Evaluation and Research, said in a public statement. He emphasized that compounded GLP-1 products have not undergone the same review process for safety, effectiveness, or quality as FDA-approved medications.

Growing market, growing scrutiny

The warnings come amid explosive demand for GLP-1 medications, which have transformed obesity treatment and become one of the pharmaceutical industry's fastest-growing sectors.

During recent shortages of brand-name products, compounding pharmacies and telehealth providers stepped in to offer alternative versions, often at lower prices and with easier access than traditional healthcare channels. Those alternatives helped fuel the rapid growth of online prescribing platforms, according to Telehealth.org.

But regulators have increasingly questioned whether some telehealth companies are blurring the distinction between FDA-approved drugs and compounded versions.

The FDA notes that compounded drugs are custom-prepared medications created for individual patients by licensed pharmacists or physicians. Unlike approved drugs, compounded medications do not undergo FDA review for safety, effectiveness, or manufacturing quality before reaching consumers.

The agency specifically warned companies against describing compounded drugs as generic equivalents of approved products, claiming they are FDA-approved, or suggesting they produce the same results as brand-name medications.

Part of a broader enforcement effort

The latest warning letters represent the newest phase of a larger enforcement campaign that began last year.

In March, the FDA issued warning letters to 30 telehealth companies over similar marketing practices involving compounded GLP-1 drugs. FDA Commissioner Marty Makary at the time described the effort as a “new era of enforcement” aimed at preventing companies from circumventing the drug approval process through mass marketing of compounded medications.

The agency has also taken steps to limit the availability of compounded versions of semaglutide and tirzepatide. In April, the FDA proposed removing the drugs from a key compounding list, a move that could significantly restrict large-scale production by outsourcing facilities and further tighten the market for compounded weight-loss medications.

Earlier this year, regulators also moved against telehealth provider Hims & Hers over a compounded weight-loss pill, citing concerns about quality, safety, and potential violations of federal law. The company later discontinued the product.

What it means for consumers

For consumers, the FDA's message is straightforward: compounded weight-loss drugs are not the same as FDA-approved medications, regardless of how they are marketed online.

While compounded drugs can play an important role when medically necessary, the agency says patients should be wary of websites that imply compounded products have received FDA approval or have been proven to perform identically to approved therapies.

The crackdown also highlights growing concerns about the direct-to-consumer telehealth model, where patients can often obtain prescriptions and medications without visiting a traditional doctor's office. Regulators argue that transparency about what consumers are receiving is essential as online healthcare services continue to expand.

What Consumers Should Know

• FDA-approved drugs undergo extensive review for safety, effectiveness, and manufacturing quality.
• Compounded drugs are not FDA-approved and are generally intended for individualized patient needs.
• Be skeptical of claims that a compounded drug is the “same as” or equivalent to an FDA-approved medication.
• Verify that telehealth providers clearly disclose whether a medication is compounded.
• Discuss weight-loss treatment options with a qualified healthcare professional before starting therapy.

Bottom line: As demand for GLP-1 weight-loss medications continues to soar, federal regulators are making clear that telehealth companies cannot market compounded alternatives as if they were FDA-approved drugs. The latest warning letters signal that enforcement efforts against misleading online advertising are likely to continue throughout 2026.